However, personal neoantigen-derived vaccines are limited to eliciting specific CD8+ T cell responses because of the lack of tumor-infiltrating lymphocytes into tumor tissues, and the deficient combination of preselected neoepitopes using in silico MHC-I and MHC-II binders58–60. Here, CD8A is linked to neoplasm.